Comparative Pharmacology
Head-to-head clinical analysis: ETOMIDATE versus HALOTHANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETOMIDATE versus HALOTHANE.
ETOMIDATE vs HALOTHANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateHalothane + Torasemide
"The risk or severity of adverse effects can be increased when Halothane is combined with Torasemide."
Clinical Note
moderateHalothane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid."
Clinical Note
moderateHalothane + Furosemide
"The risk or severity of adverse effects can be increased when Halothane is combined with Furosemide."
Clinical Note
moderateHalothane + Bumetanide
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Halothane is combined with Bumetanide."